Is the semaglutide-based weight-loss approach truly worthy of endorsement?

The meta-analysis focused on 308 participants who had lost at least 10% of their body weight while on medication and were then switched to placebo. By week 88, approximately 82.5% of participants regained at least 25% of their lost weight; about 57% regained at least 50%; and roughly 24% regained at least 75%. The greater the weight regain, the more pronounced the reversal of cardiovascular and metabolic improvements—measured by blood pressure, lipid profiles, fasting glucose, and insulin resistance indices. Participants who regained over 75% of their lost weight saw their cardiovascular and metabolic parameters revert entirely to pre-treatment levels. Some researchers have proposed reclassifying GLP-1 receptor agonists—not as 'weight-loss drugs', but as 'weight-management drugs'—to underscore the likelihood that such medications may need to be taken indefinitely. Regarding semaglutide, other controversies exist. For instance, this paper: Sylvia Hristakeva, Jūra Liaukonytė, Leo Feler, EXPRESS: The No-Hunger Games: How GLP-1 Medication Adoption is Changing Consumer Food Demand, Journal of Marketing Research (2025) doi: 10.1177/00222437251412834 Science watchdog Leonid Schneider harshly criticized this paper [2]— A clever—and quintessentially American—solution to the economic hardship many Americans may face due to Trump and the 'Make America Great Again' movement: If you can’t afford food, inject GLP-1 medications like Ozempic or Wegovy—then you won’t feel hungry! As reported by Gizmodo on December 22, 2025: Scientists from Cornell University studied grocery-shopping habits among people using GLP-1 medications. Compared with demographically similar households not using GLP-1 drugs, those using them spent less on groceries—especially on snacks. However, this reduction in grocery spending appeared to persist only during active drug use. 'Data show a clear shift in food spending after starting the medication,' said Sylvia Hristakeva, assistant professor at Cornell’s SC Johnson College of Business and lead author of the study, in a university press release. […] Approximately one-third of households reported discontinuing GLP-1 receptor agonists during the study period. Researchers observed that grocery bills for these households rebounded to baseline levels. […] 'These findings highlight the potential for GLP-1 medications to significantly reshape consumer food demand—a trend whose implications for the food industry are growing increasingly important as GLP-1 medications become more widespread,' the authors wrote.

How do weight-loss drugs 'mute' the brain’s craving for food?

How do weight-loss drugs 'mute' the brain’s craving for food? Latest research in Nature Medicine A 60-year-old female patient had electrodes implanted in her brain to record electrical signals from deep brain regions around the clock. When researchers reviewed the data, they were astonished to find that, over several months following treatment with the weight-loss drug tirzepatide, the characteristic neural activity patterns in her brain’s reward center—normally associated with intense food cravings—suddenly vanished—as if silenced by a mute button. Yet after five months, these signals reappeared. This unexpected observation became the first direct evidence in humans showing how GLP-1–class weight-loss drugs 'switch off' food cravings at the level of the brain. Published on November 17, 2025, in Nature Medicine [1], this study opens a new window into understanding the mechanism of action of these so-called 'miracle drugs'. When a surgical trial met a weight-loss drug This was not originally a study about weight-loss drugs. A team led by neurosurgeon Dr. Casey Halpern at the Perelman School of Medicine, University of Pennsylvania, was conducting an exploratory clinical trial testing whether deep brain stimulation (DBS) could help severely obese patients control compulsive eating—patients who had failed every other intervention, from bariatric surgery to behavioral therapy. The trial’s core technology involved implanting electrodes into the nucleus accumbens—a key hub of the brain’s reward system responsible for processing pleasure and motivation-driven behavior. Researchers aimed to monitor electrical activity here to identify 'biomarkers' predictive of binge-eating episodes, then deliver precisely timed electrical stimulation to interrupt such impulses. Data from the first two participants aligned with expectations: each time they reported strong food cravings, low-frequency (2–8 Hz) delta-theta brain waves in the nucleus accumbens surged markedly. This pattern functioned like a 'warning signal' preceding binge episodes. But the third participant—the woman introduced at the beginning of this article—delivered an unexpected twist. Prior to electrode implantation surgery, her primary care physician had already prescribed her tirzepatide (marketed as Mounjaro for type 2 diabetes and Zepbound for obesity) to manage her type 2 diabetes. Tirzepatide is a dual GLP-1/GIP receptor agonist and currently one of the most potent weight-loss drugs available. Tirzepatide is sold under two brand names: Mounjaro (for diabetes) and Zepbound (for obesity). A 'silencing period' in the brain’s reward center In the first few months post-surgery, researchers observed an unusual phenomenon. The patient reported she was virtually free from food-related preoccupations—cravings for pre-packaged cupcake snacks, fast-food roast beef sandwiches, and french fries had all disappeared. Her weight began to decline. Even more astonishing were the electrophysiological data: two to four months after titrating tirzepatide up to its maximum dose, low-frequency electrical activity in her nucleus accumbens nearly vanished. The delta-theta band activity—clearly evident in the first two participants and tightly linked to food cravings—was undetectable in her recordings.

GLP-1 Weight-Loss Drugs Depress Demand for Food Packaging

Sep 24, 2026

HB Fuller CEO reports GLP-1 weight-loss drugs are reducing packaged food consumption, depressing demand for adhesives and food packaging. The trend also affects food ingredient distributors, compounded by slower household formation.

icis

2026-09-24

GLP-1 Weight-Loss Drugs Depress Demand for Food Packaging

GLP-1 Weight-Loss Drugs Depress Demand for Food Packaging

FAQ